The COMPASS Trial | Circulation
NEJM on Twitter: "Original Article: Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (COMPASS trial) https://t.co/ZUZPmvmumA https://t.co/E6kAbGDi9W" / Twitter
A New Antithrombotic Strategy for Patients with Chronic CAD
Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial - The Lancet
Stroke Outcomes in the COMPASS Trial | Circulation
A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the numbers needed to treat: Applicability and relevance in Indian patients with stable cardiovascular disease | Semantic Scholar
Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances | Journal of the American College of Cardiology
![Number Needed to treat [For Benefit and Harm] (NNT-B and NNT-H) and the... | Download Scientific Diagram](https://www.researchgate.net/publication/370326321/figure/fig4/AS:11431281154040459@1682644684881/Landmark-analysis-of-the-COMPASS-trial-of-primary-efficacy-and-safety-endpoints_Q320.jpg "Number Needed to treat [For Benefit and Harm] (NNT-B and NNT-H) and the... | Download Scientific Diagram")
Number Needed to treat [For Benefit and Harm] (NNT-B and NNT-H) and the... | Download Scientific Diagram
![PDF) A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the number needed to treat [NNT]: Applicability and relevance in Indian patients with stable cardiovascular disease](https://i1.rgstatic.net/publication/327166228_A_critical_analysis_of_the_COMPASS_trial_with_respect_to_benefit-risk_assessment_using_the_number_needed_to_treat_NNT_Applicability_and_relevance_in_Indian_patients_with_stable_cardiovascular_disease/links/5dfdc67b4585159aa48d353a/largepreview.png "PDF) A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the number needed to treat [NNT]: Applicability and relevance in Indian patients with stable cardiovascular disease")
PDF) A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the number needed to treat [NNT]: Applicability and relevance in Indian patients with stable cardiovascular disease
A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the numbers needed to treat: Applicability and relevance in Indian patients with stable cardiovascular disease | Semantic Scholar
Stroke Outcomes in the COMPASS Trial | Circulation
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial | Circulation
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial - The Lancet
Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial Kelley Branch, - ppt download
Antiplatelet therapy in cardiovascular disease: Current status and future directions - Passacquale - 2022 - British Journal of Clinical Pharmacology - Wiley Online Library
Anticoagulants for stroke prevention in heart failure with reduced ejection fraction | Clinical Research in Cardiology
Critical appraisal of the COMPASS trial
Frontiers | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
COMPASS - ASA + rivaroxaban (or riva alone) vs ASA alone in stable CVD — NERDCAT
Adding Rivaroxaban to Aspirin in treatment of Indian Stable CAD patients- Analysis of COMPASS trial in India by Dr Prafulla Kerkar Et al
The COMPASS Trial | Circulation
Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial Kelley Branch, - ppt download
Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD | SpringerLink
![Number Needed to treat [For Benefit and Harm] (NNT-B and NNT-H) and the... | Download Scientific Diagram](https://www.researchgate.net/publication/370326321/figure/fig3/AS:11431281154011129@1682644684769/Major-bleeding-events-in-the-two-groups-of-the-COMPASS-trial_Q320.jpg "Number Needed to treat [For Benefit and Harm] (NNT-B and NNT-H) and the... | Download Scientific Diagram")
Number Needed to treat [For Benefit and Harm] (NNT-B and NNT-H) and the... | Download Scientific Diagram
![Number Needed to treat [For Benefit and Harm] (NNT-B and NNT-H) and the... | Download Scientific Diagram](https://www.researchgate.net/publication/370326321/figure/fig6/AS:11431281154043873@1682644685354/Proportion-of-COMPASS-eligible-patients-in-REACH-and-START-registry_Q320.jpg "Number Needed to treat [For Benefit and Harm] (NNT-B and NNT-H) and the... | Download Scientific Diagram")
Number Needed to treat [For Benefit and Harm] (NNT-B and NNT-H) and the... | Download Scientific Diagram
